TriCelX Files IND with FDA & Requests RMAT Designation for XytriX™ in Knee Osteoarthritis

Concurrent IND Filing and RMAT Request Position XytriX™ as Potential Breakthrough Biotherapeutic for Over 500 Million Osteoarthritis Patients

Mar. 30, 2026 at 10:35am

Got story updates? Submit your updates here. ›

TriCelX, Inc. has submitted a Phase 1/2 Investigational New Drug (IND) application to the FDA for XytriX™, its proprietary allogeneic umbilical cord tissue-derived mesenchymal stem cell (hUC-MSC) biotherapeutic for the treatment of adult patients with Grade I–IV Knee Osteoarthritis (KOA). Concurrent with the IND filing, TriCelX has also submitted a formal request for Regenerative Medicine Advanced Therapy (RMAT) designation, one of the FDA's highest-priority development pathways.

Why it matters

Osteoarthritis is the world's most prevalent joint disease, affecting over 500 million people globally and imposing a staggering economic burden exceeding $137 billion in the U.S. alone. Current standard-of-care interventions only manage symptoms at best, with no approved disease-modifying therapies. XytriX™ is designed to address the underlying biology of knee OA through multiple complementary mechanisms, potentially offering a transformative, disease-modifying treatment for this debilitating condition.

The details

XytriX™ is a next-generation, off-the-shelf allogeneic cell therapy derived from Wharton's jelly of donated human umbilical cords. It is designed to address the underlying biology of knee OA through immunomodulation, anti-inflammatory signaling, stimulation of endogenous progenitor cells, promotion of cartilage formation and collagen deposition, and cytoprotection against cell death. The Phase 1/2 trial will enroll approximately 50 adult subjects at TriCelX's Frisco, Texas clinical site, with participants receiving a single intra-articular injection of 30 million hUC-MSCs and being monitored over a 180-day follow-up period.

  • TriCelX submitted the IND application on March 30, 2026.
  • TriCelX concurrently submitted a formal request for RMAT designation on March 30, 2026.

The players

TriCelX, Inc.

A global translational biologics company dedicated to advancing evidence-based, personalized regenerative medicine therapies, with operations in Texas, Utah, and Antigua.

Jakes Jordaan

Founder and Chief Executive Officer of TriCelX, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“The submission of our IND and our concurrent request for RMAT designation represent defining milestones for TriCelX and, more importantly, for the hundreds of millions of patients worldwide who are suffering from osteoarthritis and have run out of options. XytriX™ is not simply another symptomatic treatment — it is designed to harness the body's own regenerative biology to address the root cause of joint destruction. We are proud of the scientific rigor embedded in every aspect of this submission and look forward to a productive collaboration with the FDA as we advance this promising therapy toward patients.”

— Jakes Jordaan, Founder and Chief Executive Officer, TriCelX, Inc.

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.